Pulmonary Hypertension

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

By

The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.

PAH-SYMPACT<sup>®</sup>: A Reliable Instrument for PAH Symptom Assessment

PAH-SYMPACT®: A Reliable Instrument for PAH Symptom Assessment

By

The Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire has good psychometric properties and can be administered in clinical practice.

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

By

The "egg-and-banana" sign is a valid computed tomography marker of pulmonary hypertension.

Oral Anticoagulant Effective in Recurrent VTE Prevention in Cancer Patients

Oral Anticoagulant Effective in Recurrent VTE Prevention in Cancer Patients

By

At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

By

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

YEARS Criteria in Pulmonary Embolism Evaluation May Reduce Need for Imaging

YEARS Criteria in Pulmonary Embolism Evaluation May Reduce Need for Imaging

By

D-dimer test adjustment based on pretest probability results may be a safe option to reduce the need for imaging during evaluation for pulmonary embolism.

Copeptin May Serve as Prognostic Biomarker for Pulmonary Embolism

Copeptin May Serve as Prognostic Biomarker for Pulmonary Embolism

By

Copeptin may be useful for identifying normotensive patients with pulmonary embolism who have a higher risk for an adverse outcome.

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

By

In patients with pulmonary arterial hypertension who were treated with a parenteral prostanoid, survival was linked with the number of guideline-recommended lower-risk and higher-risk criteria attained.

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

By

Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

By

The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

By

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

By

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

PAAT May Detect Pulmonary Vascular Disease in Preterm Infants

PAAT May Detect Pulmonary Vascular Disease in Preterm Infants

By

Regardless of neonatal lung disease status, infants born before 29 weeks' gestation demonstrated abnormal pulmonary artery acceleration time at 1-year corrected age.

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

By

In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.

Perioperative Risk Assessment in a Patient With COPD

Perioperative Risk Assessment in a Patient With COPD

By

A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

By

Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.

Pulmonary Hypertension Outcomes Predicted by NT-pro BNP

Pulmonary Hypertension Outcomes Predicted by NT-pro BNP

By

N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.

Pulmonary Hypertension Mortality Following Cardiac Catheterization

Pulmonary Hypertension Mortality Following Cardiac Catheterization

By

Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.

Pulmonary Hypertension With HFpEF Mortality Predicted by Hemodynamic Markers

Pulmonary Hypertension With HFpEF Mortality Predicted by Hemodynamic Markers

The hemodynamic parameters predict mortality and cardiac hospitalization in patients with heart failure with preserved ejection fraction.

Middle-Aged Woman With Progressive Exertional Dyspnea

Middle-Aged Woman With Progressive Exertional Dyspnea

By

A 57-year-old woman has been experiencing progressive exertional dyspnea during the past 6 months as well as a near syncopal episode while attempting to catch a taxi.

Hemodynamic markers of pulmonary hypertension in heart failure with preserved ejection fraction are associated with mortality

Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are predictors of mortality and cardiac hospitalizations in pulmonary hypertension associated with heart failure with preserved ejection fraction.

A 32-Year-Old Pregnant Woman Presents With Worsening Dyspnea

A 32-Year-Old Pregnant Woman Presents With Worsening Dyspnea

By

Several months after being diagnosed with pulmonary arterial hypertension, a 32-year-old pregnant woman presents with worsening dyspnea.

PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

By

Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions for US veterans are inconsistent with pulmonary hypertension guidelines.

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

By

Patients with pulmonary arterial hypertension may be better identified through a claims-based algorithm that includes ICD-9-CM codes, specific pulmonary arterial hypertension medications, echocardiography, and right heart catheterization.

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

By

Women with pulmonary arterial hypertension experienced better long-term prognosis than men with PAH.

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

By

Enlargement of the right atrium is associated with an increased risk for supraventricular arrhythmias in PAH.

Varicose Veins May Increase Risk for Pulmonary Embolism

Varicose Veins May Increase Risk for Pulmonary Embolism

Varicose veins may increase the risk for pulmonary embolism and peripheral artery disease.

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

By

Peak circulatory power offers greater value than peak oxygen uptake and ventilation in predicting cardiac events in patients with idiopathic PAH.

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

By

Hypoxemia in individuals with idiopathic PAH is associated with increased mortality risk.

Pulmonary Embolism Rule-out Criteria non-inferior to usual care for patients at low-risk for pulmonary embolism

In this multicenter, randomized controlled study, the Pulmonary Embolism Rule-out Criteria (PERC) strategy resulted in significantly fewer uses of CT pulmonary angiography, reduced ED length of stay, and fewer hospital admissions.

Sign Up for Free e-newsletters